557 related articles for article (PubMed ID: 16384610)
1. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
3. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
6. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
[TBL] [Abstract][Full Text] [Related]
9. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
10. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
11. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
[TBL] [Abstract][Full Text] [Related]
14. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
[TBL] [Abstract][Full Text] [Related]
15. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
[TBL] [Abstract][Full Text] [Related]
16. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN; Marchion DC; Basso AD; Rosen N
Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
[TBL] [Abstract][Full Text] [Related]
17. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]